

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:10:39 ON 08 FEB 2008

=> file medine embase biosis caplus

'MEDINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 11:10:56 ON 08 FEB 2008

FILE 'EMBASE' ENTERED AT 11:10:56 ON 08 FEB 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:10:56 ON 08 FEB 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:10:56 ON 08 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s Lubeck(w)protocol or Luebeck(w)protocol

L1 5 LUBECK(W) PROTOCOL OR LUEBECK(W) PROTOCOL

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 2 DUP REM L1 (3 DUPLICATES REMOVED)

=> dis ibib abs l2 1-2

L2	ANSWER 1 OF 2	MEDLINE on STN	DUPLICATE 1
ACCESSION NUMBER:	1998427993	MEDLINE	
DOCUMENT NUMBER:	PubMed ID: 9755411		
TITLE:	New approaches to ovarian stimulation.		
AUTHOR:	Diedrich K; Felberbaum R		
CORPORATE SOURCE:	Department of Obstetrics and Gynecology, Medical University		

of Lubeck, Germany.
SOURCE: Human reproduction (Oxford, England), (1998 Jun) Vol. 13
Suppl 3, pp. 1-13; discussion 14-7. Ref: 43
Journal code: 8701199. ISSN: 0268-1161.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199811
ENTRY DATE: Entered STN: 6 Jan 1999
Last Updated on STN: 6 Jan 1999
Entered Medline: 17 Nov 1998

AB Suppression of endogenous hormone production by gonadotrophin-releasing hormone (GnRH) agonists followed by controlled ovarian hyperstimulation (COH) with human gonadotrophins, especially the so-called 'long protocol' has developed from second-line into first-line therapy. Due to this attitude premature luteinization can be safely avoided, enhancing therapeutic efficacy. Recombinant preparations of human follicle stimulating hormone (FSH) have been proven to be effective within COH according to the long protocol. The high purity of these compounds may have clinical advantages. GnRH antagonists could be successfully introduced in COH protocols. Also, daily injections in the midcycle phase according to the 'Lubeck protocol', as single or only dual administrations around day 9 seem to abolish any premature LH rises. Due to their different pharmacological mode of action, based on a classic competitive receptor blockage GnRH antagonists avoid any flare-up period and allow ovarian stimulation to start within the spontaneous cycle. Pregnancy rates are comparable to those after long protocol stimulation. Combination of softer stimulation regimes like clomiphene citrate and low dose HMG with midcycle administration of GnRH antagonists may be the way to a cheap, safe and efficient ovarian stimulation. It seems to be high time for modest forms of ovarian stimulation, lowering burden and risk for our patients.

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:511666 CAPLUS
DOCUMENT NUMBER: 129:255149
TITLE: Multiple dose protocol for the administration of
GnRH-antagonists in IVF: the "Lubeck-
protocol"
AUTHOR(S): Felberbaum, R.; Diedrich, K.
CORPORATE SOURCE: Department of Obstetrics and Gynecology, Medical
University of Lubeck (D), Germany
SOURCE: In Vitro Fertilization and Assisted Reproduction,
Proceedings of the World Congress of in Vitro
Fertilization and Assisted Reproduction, Vancouver, B.
C., May 24-28, 1997 (1997), 397-404. Editor(s):
Gomel, Victor; Leung, Peter C. K. Monduzzi Editore:
Bologna, Italy.
CODEN: 66MRAP
DOCUMENT TYPE: Conference
LANGUAGE: English

AB Due to their different pharmacol. mode of action GnRH-antagonists are able to suppress serum-concns. of LH within hours. Instead of "down-regulation" and "desensitization" a classic competitive blockage of the GnRH-receptors on the cell-membrane of the gonadotrophic cells seems to take place. The "flare up", typical for agonistic GnRH-analogs is completely avoided. While the first generation of GnRH-antagonists caused important problems due to allergic reactions, which inhibited their clin. introduction, Cetrorelix and Ganirelix as representatives of the youngest generation of these compds. seem to avoid these disturbances completely.

Cetrorelix was introduced first in our IVF-program to scrutinize the possibility of avoiding premature LH-surges. All patients were treated with human menopausal gonadotropin (HMG), starting on day 2. From day 7 until induction of ovulation by human chorionic gonadotropin (HCG) Cetrorelix is administered s.c. in a daily fashion. Starting with a dosage of 3-mg Cetrorelix/day no premature LH-surges could be observed. Also, 1 mg/day, 0.5 mg/day and 0.25 mg/day administered according to the described "Lubeck-protocol" avoided any premature LH-surges. The mean courses of FSH and LH in the different dosage groups were quite similar with a profound suppression of LH. Estradiol concns. reflected a satisfactory follicular development. The fertilization-rate after IVF in cases of tubal infertility or ICSI in cases of male subfertility were within the range to be expected after normal oocyte maturation.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	15.05	15.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.80	-0.80

STN INTERNATIONAL LOGOFF AT 11:13:01 ON 08 FEB 2008